Profile data is unavailable for this security.
About the company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
- Revenue in SEK (TTM)25.44bn
- Net income in SEK3.51bn
- Incorporated1939
- Employees1.81k
- LocationSwedish Orphan Biovitrum AB (publ)Tomtebodavagen 23ASOLNA 171 65SwedenSWE
- Phone+46 86972000
- Websitehttps://www.sobi.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | 37.73bn | 4.47bn | 103.62bn | 8.80k | 23.37 | -- | 16.04 | 2.75 | 60.12 | 60.12 | 507.19 | -- | -- | -- | -- | 33,782,390.00 | -- | 9.24 | -- | 13.43 | 57.87 | 53.30 | 11.84 | 12.72 | -- | 13.17 | -- | 8.64 | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | 12.47 |
| Eisai Co Ltd | 51.07bn | 2.27bn | 107.48bn | 11.07k | 45.73 | 1.66 | 20.84 | 2.10 | 113.89 | 113.89 | 2,559.71 | 3,134.76 | 0.5385 | 0.8878 | 3.72 | 66,309,300.00 | 2.52 | 5.29 | 3.32 | 7.16 | 79.40 | 76.91 | 4.69 | 8.68 | 1.74 | -- | 0.1655 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Sichuan Biokin Pharmaceutical Co Ltd | 8.77bn | 5.70bn | 107.66bn | 2.09k | 18.88 | 16.92 | -- | 12.27 | 9.48 | 9.48 | 14.58 | 10.58 | 1.40 | 1.81 | 64.16 | 2,802,843.00 | 90.79 | -- | 138.20 | -- | 95.33 | -- | 64.99 | -- | 2.89 | -- | 0.2807 | -- | -20.11 | -- | -176.40 | -- | -- | -- |
| Ipsen SA | 39.81bn | 7.69bn | 109.38bn | 5.33k | 14.18 | 2.30 | 9.19 | 2.75 | 7.94 | 8.15 | 41.11 | 48.94 | 0.5436 | 1.98 | 5.02 | 645,089.20 | 10.47 | 9.71 | 14.29 | 13.33 | 82.01 | 82.76 | 19.27 | 16.02 | 0.9771 | 46.18 | 0.0902 | 19.23 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
| Catalent Inc | 46.77bn | -11.14bn | 114.28bn | 16.90k | -- | 2.96 | -- | 2.44 | -5.75 | -5.75 | 24.14 | 19.91 | 0.4268 | 4.88 | 3.01 | 259,230.80 | -10.16 | 0.0124 | -11.61 | 0.014 | 21.75 | 28.93 | -23.81 | 0.0278 | 1.93 | 0.6681 | 0.5765 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Swedish Orphan Biovitrum AB (publ) | 25.44bn | 3.51bn | 121.32bn | 1.81k | 33.88 | 3.16 | 16.86 | 4.77 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Lupin Ltd | 26.40bn | 2.87bn | 125.01bn | 21.87k | 43.60 | -- | 29.87 | 4.73 | 49.50 | 49.50 | 454.84 | -- | -- | -- | -- | 9,510,284.00 | -- | 1.43 | -- | 2.22 | 67.58 | 58.52 | 11.00 | 2.04 | -- | 9.07 | -- | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Zydus Lifesciences Ltd | 26.17bn | 5.29bn | 125.88bn | 26.24k | 23.87 | -- | 19.90 | 4.81 | 41.28 | 41.51 | 204.01 | -- | -- | -- | -- | 7,856,441.00 | -- | 9.05 | -- | 14.01 | 70.22 | 61.15 | 20.29 | 14.33 | -- | -- | -- | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Recordati Industria Chmc Frmctc SpA | 25.77bn | 4.49bn | 128.70bn | 4.46k | 29.78 | 6.07 | 20.48 | 4.99 | 1.78 | 1.78 | 10.31 | 8.75 | 0.5289 | 1.76 | 4.96 | 499,152.90 | 9.20 | 11.67 | 11.78 | 15.02 | 67.10 | 70.43 | 17.40 | 21.45 | 0.9457 | 6.74 | 0.4818 | 42.46 | 12.36 | 9.02 | 24.61 | 4.50 | 81.68 | 5.46 |
| Dr Reddy's Laboratories Ltd | 36.76bn | 7.07bn | 132.19bn | 26.34k | 18.73 | -- | 14.74 | 3.60 | 66.74 | 66.74 | 347.18 | -- | -- | -- | -- | 10,989,370.00 | -- | 11.37 | -- | 16.02 | 70.80 | 65.86 | 19.22 | 14.63 | -- | 36.60 | -- | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Mankind Pharma Ltd | 13.52bn | 2.49bn | 133.67bn | 19.54k | 53.72 | -- | 43.70 | 9.89 | 48.91 | 48.91 | 265.43 | -- | -- | -- | -- | 5,450,142.00 | -- | -- | -- | -- | 69.93 | -- | 18.69 | -- | -- | 90.42 | -- | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 14.25bn | 2.29bn | 134.83bn | 14.92k | 58.93 | 14.15 | 40.83 | 9.46 | 53.25 | 53.25 | 331.63 | 221.72 | 0.7525 | 1.22 | 6.35 | 7,525,369.00 | 12.08 | 8.34 | 17.95 | 13.03 | 75.52 | 71.78 | 16.06 | 13.18 | 0.7444 | 9.32 | 0.2941 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Biomarin Pharmaceutical Inc | 29.39bn | 3.44bn | 135.53bn | 3.40k | 40.33 | 2.35 | 30.08 | 4.61 | 1.65 | 1.65 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Beijing Wantai Biolog Pha Ent Co Ltd | 3.74bn | -441.18m | 136.46bn | 3.84k | -- | 7.32 | -- | 36.53 | -0.2393 | -0.2393 | 1.97 | 9.82 | 0.1596 | 0.7843 | 0.7758 | 647,931.10 | -1.89 | 24.08 | -2.26 | 31.80 | 69.01 | 85.18 | -11.84 | 34.95 | 4.18 | -- | 0.0238 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Shionogi & Co Ltd | 29.12bn | 10.76bn | 136.85bn | 4.96k | 12.23 | 1.45 | 11.37 | 4.70 | 180.70 | 180.70 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
Data as of Oct 31 2024. Currency figures normalised to Swedish Orphan Biovitrum AB (publ)'s reporting currency: Swedish Krona SEK
21.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 21.01m | 5.93% |
| Swedbank Robur Fonder ABas of 30 Sep 2024 | 10.64m | 3.00% |
| Polar Capital LLPas of 30 Aug 2024 | 8.74m | 2.47% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 7.80m | 2.20% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 6.52m | 1.84% |
| AMF Fonder ABas of 30 Jun 2024 | 6.30m | 1.78% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 4.13m | 1.17% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 4.04m | 1.14% |
| Artisan Partners LPas of 30 Sep 2024 | 3.30m | 0.93% |
| Carnegie Fonder ABas of 30 Sep 2024 | 2.88m | 0.81% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
